Year Founded
2016
Ownership
Public
Employees
~133
Stage
Preclinical
Modalities
Nautilus Biotechnology General Information
Development stage company creating a platform technology for quantifying and unlocking the complexity of the proteome. Has not yet commercialized any products.
Drug Pipeline
No pipeline data available
Key Partnerships
Genentech, Amgen, The University of Texas MD Anderson Cancer Center, Abcam
Nautilus Biotechnology Funding
Deal Type | Date | Amount | Status | Stage |
---|
To view Nautilus Biotechnology's complete valuation and funding history, request access »
Nautilus Biotechnology Investors
Cercano Management (formerly Vulcan Capital)
Investor Type: Venture Capital
Holding: Minority
Perceptive Advisors
Investor Type: Venture Capital
Holding: Minority
Defy Partners
Investor Type: Venture Capital
Holding: Minority
You're viewing 3 of 8 investors. Get the full list »